FDG PET
This article was originally published in The Gray Sheet
Executive Summary
Medicare Coverage Advisory Committee's Diagnostic Imaging Panel will hold a Jan. 10 meeting to discuss whether and when it is scientifically justified to use fluoro-D-glucose positron emission tomography or other neuro-imaging devices for the diagnosis and patient management of Alzheimer's disease, a Nov. 23 Federal Register notice announces. The meeting will focus on asymptomatic patients who are at high risk of AD due to positive family history, patients with mild cognitive impairment or similar syndrome and patients with dementia. The deadline for presentations and comments is Dec. 27...